YO8 - HIPEC in Ovarian cancer. Experience in Kazakh Institute of Oncology and Radiology.

Case summary

According to Globocan 2020, ovarian cancer (OC) is the eighth most common cancer in women and one of the leading causes of death from gynecological cancer. Five-year survival rates in patients with ovarian cancer are low, less than 45%. In 2020, 313,959 new cases of OC were registered, 70% of which are registered at an advanced stage. In Kazakhstan, malignant neoplasms of the ovaries occupy the 8th ranking position among malignant tumors. Despite the improvement in approaches to the diagnosis and treatment of OC, a high level of neglected cases and low 5-year survival rates in OC patients remain.

Since 2019 HIPEC has been performed in KazIOR for patients with ovarian cancer. From 2019 to 2021, 14 operations were performed, 7 (50%) of them in the volume of optimal cytoreduction, 7 (50%) operations in the volume of non-optimal cytoreduction, all operations were performed by abdominal access. 12 (85%) patients with stage 3c, 1 (7%) patient with stage 3b, 1 (7%) with stage 4a. Indications for HIPEC were: index of peritoneal carcinomatosis (PCI) less than 15, absence of severe concomitant diseases, verified ovarian cancer, histological forms: serous, mucinous carcinoma.

11 (78%) patients with primary ovarian cancer were operated on with HIPEC after 3-4 courses of NAPCT according to the PP scheme, 3 (21%) patients with recurrent cancer after combined treatment (chemo + surgery).

11 (78%) patients with a histological conclusion of serous carcinoma, 3 (21%) patients with mucinous adenocarcinoma.

Concomitant diseases were in 10 (71%) patients of them: type 2 diabetes mellitus in 2 (14%) patients, arterial hypertension in 5 (35%) patients, chronic pyelonephritis in 3 (21%) patients, bronchial asthma in 1 (7 %) of the patient, chronic bronchitis in 1 (7%) patient, chronic cholecystitis in 1 (7%) patient, moderate anemia in 1 (7%) patient.

In 2 (14%) patients, a complication after HIPEC in the form of acute renal failure was noted, 2 (14%) patients died from the progression of oncological disease.

Considering the data for a two-year study, it can be argued that intra-abdominal hyperthermic chemotherapy is a safe treatment option for patients with ovarian cancer. Evaluation of effectiveness, overall and disease-free survival will be carried out after 5 years.

Clinical trial identification

Editorial acknowledgement